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Abstract 
Chymase, the major chymotryptic proteinase of human mast cells, can be released in substantial quantities following mast cell 
activation. As this enzyme is stored in the secretory granules in its fully active form, we have investigated various factors which might 
regulate its activity in storage and upon release. Chymase was purified from human skin by high salt extraction, cetylpyridinium chloride 
precipitation, heparin agarose affinity chromatography and gel filtration. Neither the addition of Mg 2+ or Ca 2+ (0.3-10 mM) nor their 
sequestration by EDTA had any effect on the rate of cleavage of the synthetic substrate N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide. 
Monovalent cations (Na +, K +) enhanced enzyme activity, but only at non-physiological concentrations (0.5-3.0 M), suggesting an ionic 
strength effect. At constant I = 0.15, enzyme activity was strongly pH-dependent: atpH 5.5 (the approximate pH of the mast cell granule) 
the activity was only 10% of t~at at pH 7.5 (the approximate pH of the extracellular space). Heparin, which is stored with chymase in the 
mast cell granule, accentuated this difference by enhancing activity at pH 7.5 by 33% and depressing it at pH 5.5 by 40%. Histamine at 
concentrations upto 50 mM (1= 0.15) had little effect on chymase activity at either pH, although igh concentrations did attenuate the 
actions of heparin. It is concluded that pH and the interaction with heparin are central to the regulation of chymase activity within the 
granule and following release. 
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1. Introduction 
Chymase (EC 3.4.21.39) is a cbymotrypsin-like s rine 
proteinase stored and secreted by a major subpopulation of 
mast cells [1,2]. Its absence or presence has been used to 
classify mast cells into two subsets; the MC T cells which 
contain only tryptase (a trypsin-like serine proteinase), and 
the MCTc cells, which contain both tryptase and chymase 
[3]. These two sets of cells differ both in granule content 
and in tissue distribution; the MC T cells tend to be most 
numerous in the mucosal tissues of the respiratory and 
intestinal tracts, while the MCTc cells predominate in the 
submucosa nd connective tissue and are especially abun- 
Abbreviations: Aces, N-[2-acetamido]-2-aminoethanesulfonic acid;
Amp, 2-amino-2-methylpropan-l-ol; BAPNA, N-benzoyl-DL-arginine- 
p-nitroanilide; Mes, 2-[N-morpholino]ethanesulfonic acid; SucAAPF- 
pNA, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide. 
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dant in skin. The amount of chymase in MCTc cells has 
been estimated at 4.5 pg cell-i [4]. This compares with 1 
pg cell-~ for cathepsin G and elastase in neutrophils and 
10-35 pg cell 1 for tryptase in mast cells [2]. Chymase is 
stored in the same mast cell granules as tryptase, heparin 
and histamine, and is released upon mast cell activation. 
Actions which have been attributed to chymase include the 
highly efficient conversion of angiotensin I to angiotensin 
II [5], degradation of neurotensin [6], activation of inter- 
leukin- 1/3 [7], degradation of interleukin-4 [8], and induc- 
tion of microvascular leakage and neutrophil accumulation 
[9,10]. 
Comparison of the N-terminal sequence of the mature 
enzyme with the sequence deduced from cDNA indicates 
that chymase is synthesized as a preproenzyme [11]. The 
signal peptide is removed to produce the proenzyme which 
differs from the mature enzyme by the dipeptide Gly-Glu- 
at the N-terminus, similar to many granulocyte proteinases 
[12,13]. Studies with various recombinant constructs 
demonstrated that the proenzyme is catalytically inactive 
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[14]. However, cleavage of the N-terminal dipeptide with 
an unfractionated lysate of a lymphoma cell line yielded a 
fully active enzyme with properties very similar to native 
chymase. Although the mast cell enzyme responsible for 
this maturation step has not been identified or charac- 
terized, the dipeptidase in this lymphoma cell lysate was 
optimally active between pH 5 and 6, which prompted the 
authors to speculate that chymase is packaged to the 
developing mast cell granule as the inactive proenzyme 
and subsequently activated uring the acidification which 
accompanies maturation of the granule. A similar scheme 
has been proposed for cathepsin G and neutrophil elastase, 
which both require acidification of a post-Golgi compart- 
ment for removal of a N-terminal dipeptide prosequence 
[ 15,16]. Chymase is then stored in the mast cell granule in 
an apparently active form, as demonstrated histochemically 
with chromogenic substrates [17]. 
It would be highly unusual for a degradative enzyme to 
be fully active under conditions of storage, especially if it 
can degrade itself as has been reported for chymase [ 18]. It 
is therefore likely that some means other than covalent 
modification controls the activity of chymase during stor- 
age and release. General factors which modulate the activ- 
ity of enzymes include inorganic cations, ionic strength, 
and pH. The concentrations of inorganic cations in mast 
cell granules are not well documented, but a pH of 5.55 + 
0.06 has been reported for granules isolated from rat 
peritoneal mast cells [19]. Heparin and histamine, which 
are stored with chymase in the mast cell granule, have 
been reported to affect he activity of a variety of enzymes. 
Heparin can activate tissue-type plasminogen activator [20], 
stabilise mast cell tryptase [21], inhibit pbospholipase A 2 
[22], alter the substrate specificity of mouse T-cell serine 
proteinase 1 [23], and alter the susceptibility to physio- 
logical inhibitors of thrombin [24] and elastase [25]. His- 
tamine, which is present at an estimated 100 mM within 
the granule, inhibits tryptase by 83% at only one tenth of 
that concentration [26]. In the present study, we have 
systematically examined the potential importance of these 
various factors on the regulation of chymase activity dur- 
ing storage and following release from mast cells. 
Rad (Hemel Hempstead, UK), Sigma (Poole, UK) or BDH 
(Poole, UK). AA5 (anti-tryptase monoclonal ntibody) was 
produced as described previously [27], purified polyclonal 
IgG raised against cathepsin G in sheep was kindly do- 
nated by Dr. D. Burnet (Birmingham, UK), and polyclonal 
rabbit serum raised against chymase was kindly donated 
by Dr. N. Schechter (Philadelphia, USA). 
2.2. Chymase purification 
Skin obtained from amputated limbs and apronectomy 
operations was passed several times through a meat grinder 
and extracted three times with low salt buffer (1 mm 
EDTA, 50 mm Mes, adjusted with NaOH to pH 6.8), then 
three times with high salt buffer (2.0 M NaC1, 1 mm 
EDTA, 50 mM Mes (pH 6.8)) [28]. Each high salt extract 
was mixed with an equal volume of 10% cetylpyridinium 
chloride and left to stir overnight at 4 ° C to precipitate 
proteoglycans [29]. After centrifugation at 30 000 × g for 
30 min, the supernatants were successively filtered through 
Whatman GF/F  and 0.45 /~m pore Millipore membranes. 
The ionic strength was adjusted to 2 M NaCI prior to 
concentration i a Pellicon tangential flow ultrafiltration 
system (Millipore, Watford, UK) fitted with a PLGC mem- 
brane (10 kDa nominal cut-off). The retentate was diluted 
5-fold with 10 mM Mes (pH 6.8), and concentrated again. 
The system was then washed by recirculating 200 ml 
Buffer A (0.4 M NaC1, 10 mM Mes (pH 6.8)) for 10 min, 
and the combined retentate and wash were applied to a 
4.5 X 1.3 cm column of heparin-agarose equilibrated with 
Buffer A at a flow rate of 0.50 ml min -1 cm -2. The 
column was washed with more than twelve bed volumes of 
Buffer A followed by an 80 ml gradient from 0.4 to 2.0 M 
NaCI in 10 mM Mes (pH 6.8). Fractions were pooled and 
concentrated in C-10 Centricon centrifugal concentrators 
(Amicon, Stonehouse, Glos., UK) prior to being loaded on 
an 88 X 2.5 cm column of Sephacryl S-200 equilibrated 
with 2.0 M NaCI, 100 mM Mes (pH 6.8). The chymase- 
containing fractions were pooled and concentrated asabove 
and dispensed into 200 /zl samples before storage at 
- 70  ° C .  
2. Materials and methods 
2.1. Materials 
Heparin agarose was obtained from Muratech (Ayles- 
bury, Bucks., UK) and Sephacryl S-200 from Pharmacia 
(Milton Keynes, UK). Human neutrophil cathepsin G and 
heparin (porcine intestinal mucosa, molecular mass range 
of 13-15 kDa) were purchased from Calbiochem (Not- 
tingham, UK), biotinylated antibodies to mouse IgG, per- 
oxidase-conjugated antibodies to rabbit IgG and strepta- 
vidin-horseradish peroxidase conjugate from Dako (High 
Wycombe, Bucks., UK), and all other reagents from Bio- 
2.3. Enzyme assays 
Chymase activity during purification was monitored by 
the hydrolysis of 0.7 mM N-succinyl-Ala-Ala-Pro-Phe-p- 
nitroanilide (SucAAPF-pNA) in 1.5 M NaC1, 0.3 M Tris- 
HC1 (pH 8.0), 4.5% dimethylsulfoxide. Most characterisa- 
tion studies were done in 0.12 M NaCI, 0.05 M Tris-HC1 
(pH 7.6), 4.5% dimethylsulfoxide. Buffers used for pH 
profile studies were formulated to maintain a constant 
ionic strength ( I  = 0.15) [30] and contained either 50 mM 
acetic acid, 50 mM N-[2-acetamido]-2-aminoethane- 
sulfonic acid (Aces), 100 mM Tris, 50 mM NaC1 or 100 
mM Aces, 52 mM Tris, 52 mM 2-amino-2-methyl-l-pro- 
panol (Amp), 50 mM NaC1, adjusted to the appropriate pH 
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with either HCI or NaOH. Tryptase was assayed using 
N-benzoyl-DL-arginine-p-nitroanilide (BAPNA) [27], and 
elastase was assayed with N-succinyl-Ala-Ala-Ala-p-nitro- 
anilide using the same buffer as BAPNA. Assays were 
performed in microtitre plates which had been previously 
blocked with 3% gelatine in phosphate-buffered saline 
containing 0.2% Tween-20 [31]. In all assays, 10 /zl of 
sample was mixed in a total reaction volume of 100 /zl. 
Multiple readings at 410 nm were taken using the kinetics 
programme of a Dynatech MR5000 platereader (Bi- 
llingshurst, West Sussex, UK), and reaction rates calcu- 
lated by linear regression, assuming an extinction coeffi- 
cient of 8800 M-  1 cm- 1 for p-nitroaniline and an average 
diameter of 6.6 mm for each well in the microtitre plate. 
Kinetic constants were calculated by the Cornish-Bowden 
direct linear plot method adapted to a spreadsheet program 
on a PC. 
2.4. Other assays 
Protein was determined with Brilliant blue G [32] with 
bovine serum albumin (BSA) as standard. Uronic acids 
were determined by the carbazole method [33] with glu- 
curonolactone and heparin as standards. 
2.5. Electrophoresis and Western blotting 
SDS-PAGE was perfornled on 10% gels. The gels were 
stained with the Bio-Rad silver stain according to manu- 
facturer's pecifications. Western blotting was carried out 
in a wet transfer system and after blocking with 3% 
gelatine, blots were probed with the appropriate antibody, 
and developed by treatment with the corresponding sec- 
ondary antibody followed, if appropriate, by a strepta- 
vidin-horseradish peroxidase conjugate. Colour was devel- 
oped with diaminobenzidine. 
3. Results 
3.1. Purification 
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. . . . .  97 
66 
~'  45  
........ 31 
~i~i~;ii~ 21 .7  
~ 14.4 
Fig. 1. SDS-PAGE and Western blotting of purified chymase. Lane 1: 
purified human skin chymase on silver-stained gel (10% T). Lane 2: 
purified human skin chymase on Western blot probed with rabbit anti- 
serum to human chymase. Lane 3: biotinylated molecular mass tandards 
on Western blot probed with streptavidin-horseradish peroxidase. Molecu- 
lar mass expressed in kDa. 
Chromatography on heparin agarose resolved a major 
peak of chymotryptic activity, which eluted at 1.1 M NaCI, 
and two smaller peaks. The major peak, containing 65% of 
the recovered activity, was further purified by chromatog- 
raphy on Sephacryl S-200, eluting at a Kav equivalent to 
34 kDa. The final preparation of chymase had a specific 
activity of 33 /xmol min-1 mg-1 and was devoid of any 
tryptase or elastase activity. SDS-PAGE followed by silver 
staining revealed a diffuse band at 30 kDa which reacted 
with antibodies to chymase in western blots (Fig. 1). Some 
low molecular mass material, which migrated at the front 
and reacted weakly with antibodies to chymase, was also 
present. There was no reaction in western blots with 
antibodies to tryptase or cathepsin G, though in positive 
control experiments, these antibodies bound to purified 
tryptase and cathepsin G, respectively. 
Chymase binds to proteoglycans at low concentrations 
of salt, a property that i,; exploited both in extraction 
(removal of 80% of extractable proteins with low salt 
buffer before release of chymase with high salt buffer) and 
in purification (heparin-agarose affinity chromatography). 
However, proteoglycans are also extracted by high salt 
buffer and can interfere with the subsequent affinity chro- 
matography. Cetylpyridinium chloride is commonly used 
to precipitate proteoglycans and glycosaminoglycans, and 
has been used successfully in the purification of tryptase 
from human lung [29]. Its use in the purification of chy- 
mase from human skin not only resulted in the precipita- 
tion of the proteoglycans, but also of 80% of the total 
protein, with 85-95% of the chymase remaining in the 
supernatant. 
3.2. Adsorption to vessel surfaces 
Chymase appeared to adsorb strongly to the walls of the 
microtitre plates used for enzyme assay with a concomitant 
loss of activity. This tendency to stick to container surfaces 
has been previously reported [34], and overcome by the 
inclusion of Triton X-100 in all buffers [14,18,34]. How- 
ever, as Triton X-100 might affect the properties of chy- 
mase under investigation in this study, alternative mea- 
sures to counteract adsorption were sought. Prior coating 
of the microtitre plates with blocking agents (Tween-20, 
BSA, gelatine, skimmed milk powder) [31] was found to 
enhance nzyme activity, the degree of enhancement (40%) 
being independent of the blocking agent used. As gelatine 
gave the lowest background and least interference in other 
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assays, it was the blocking agent of choice for all subse- 
quent assays. 
Chymase activity was also enhanced by the inclusion of 
BSA or gelatine in the assay medium. The degree of 
enhancement depended on the purity of the chymase: the 
more pure the sample, the greater the effect, as if endoge- 
nous proteins had a blocking effect comparable to the 
added protein. For example, in crude extracts, addition of 
exogenous protein had no effect, while with partially puri- 
fied enzyme, it stimulated activity in uncoated plates but 
not in coated plates, and with the final preparations of 
purified chymase, the addition of BSA or gelatine en- 
hanced activity even in coated plates. This degree of 
enhancement (20-80%) with highly purified chymase sug- 
gests that in the absence of other proteins in solution, prior 
blocking of the plates is not sufficient o prevent adsorp- 
tion. Therefore, characterisation studies of chymase rou- 
tinely included a treatment with BSA (100/~g ml- ~ ) as an 
additional control. 
Loss of chymase activity on storage was also affected 
by protein concentration. There was relatively little loss of 
activity when crude extracts were stored frozen. However, 
the dilute yet highly purified fractions eluted from the 
Sephacryl S-200 column lost activity very rapidly in stor- 
age at -70°C;  in one instance, more than 90% of the 
activity was lost after only 16 days. Concentrating these 
fractions 15-fold prior to freezing reduced this loss to less 
than 20% after a month in storage (data not shown). 
3.3. Effects of inorganic cations 
Under approximately physiological conditions (0.12 M 
NaCI, 0.05 M Tris-HCl (pH 7.6)), Mg 2+ and Ca 2+ bad no 
effect on the activity of purified chymase over the range of 
0.3 to 10.0 mM. Similarly, addition of EDTA (10 mM) 
had no effect on activity, suggesting that even trace levels 
of divalent cations were not necessary for full activity. The 
activity obtained under these conditions was substantially 
less than that observed with the high salt buffer used in 
routine assays during purification. A dose-response curve 
showed that activity increased with increasing NaC1 con- 
centration to 2 M, and thereafter appeared to reach a 
plateau to 3 M (Fig. 2). KC1 had a similar effect (results 
not shown). Approximately the same degree of stimulation 
by NaC1 was seen regardless of whether the plates were 
uncoated, coated with gelatine, or whether Triton X-100 or 
BSA was present to reduce adsorption to plate walls, 
strongly suggesting this stimulation is a direct effect of 
ionic strength on the enzyme, independent of the effects of 
adsorption to vessel walls. 
3.4. Effects of heparin and pH 
At mass ratios relative to chymase of 0.1:l to 30:1 
(0.0075 to 2.25 ~g ml- l ) ,  heparin, but not chondroitin 
sulfate C or dextran sulfate, enhanced the activity of 
2.5 -  
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Fig. 2. Effect of NaCI concentration on chymase activity. Purified 
chymase (75 ng ml -  I ) was assayed in 0.05 M Tris-HCl (pH 8.0), with 
SucAAPF-pNA (0.7 raM) as substrate. Values relative to the activity at 
0.15 M NaCI are expressed as mean_+ S.E. (n = 3). 
purified chymase in a dose-dependent manner in the pres- 
ence of 0.12 M NaC1, 0.05 M Tris-HCl (pH 7.6), although 
the degree of enhancement (approximately 40% at 30:1 
mass ratio) was comparable to that produced by the same 
amount of BSA or gelatin. Marked differences were, how- 
ever, observed between heparin and BSA in their effect on 
the pH profile of the enzyme. At constant ionic strength 
( I=  0.15), all three treatments (no addition, 100 /.zg ml -~ 
heparin, 100 /zg ml -~ BSA) produced a monotonic in- 
crease in activity with increasing pH from 4.0 to 10.0 with 
a slight drop at pH 10.5 (Fig. 3). Whereas BSA enhanced 
chymase activity at all pH values, heparin stimulated activ- 
ity only at pH values greater than 6.0; below pH 6.0 it 
depressed it (P  = 0.0001, P < 0.0001, and P -= 0.65 for 
pH 5.0, 5.5, and 6.0, respectively, by Student's t-test). 
Consequently, heparin accentuated the inhibitory effects of 
low pH. Either in the presence of BSA or in the absence of 
any additive, the activity of chymase at pH 5.5 (the 
approximate pH of the mast cell granule) was 10% of the 
activity at pH 7.5. In the presence of heparin, activity at 
pH 5.5 was only 5% of the activity at pH 7.5. Incubation 
for 1 h at 20 ° C at pH 4.0-6.0 followed by assay at pH 8.0 
demonstrated that chymase was stable over this range, and 
even retained more activity than after incubation at pH 7.5. 
The action of these macromolecules was examined in 
more detail at pH 5.5, 6.0, and 7.5 (Table 1). For all three 
treatments, the Vma x decreased with decreasing pH, but 
whereas the Vma x of chymase + BSA remained greater 
than the Vm~ x of chymase alone, the Vma X of chymase + 
heparin was greater than the Vma ~ of chymase alone at pH 
7,5, equal to it at pH 6.0, and less than it at pH 5.5. The 
K m of the enzyme was also affected by these treatments. 
Chymase alone had little change in K m with the decrease 
in pH, but a marked increase was seen in the presence of 
both heparin and BSA. 
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pH Fig. 4. Effect of histamine concentration on chymase activity in the 
presence or absence of heparin and BSA. Purified chymase was assayed 
Fig. 3. pH profile of purified chymase: effect of heparin and BSA. (A) using 0.7 mM SucAAPF-pNA with (0 )  no addition, (O) 100 /zg ml -I 
Purified chymase (150 ng ml - ] )  was assayed using 0.7 mM SucAAPF- heparin, or ( - )  100 /xg ml -I BSA in (A) 0.05 M Tris-HC1 (pH 7.6) 
pNA in acetic acid/Aces/Tris buffer (pH 4.0-6.5) or Aces/Tris/Amp (enzyme concentration = 0.15 /xg ml-I ), or (B) 0.05 M acetic acid, 0.05 
buffer (pH 6.0-10.5)(1=0.15) with (0 )  no addition, (©) 100 /zg/ml M Aces, 0.10 M Tris (pH 5.5) (enzyme concentration= 1.2 /xg ml-I).  
heparin, or (A)100 /zg/ml BSA. Activity is expressed as percentage of The concentration of NaC1 and buffer were adjusted to maintain a 
t 2 activity at pH 7.5 with no addition. (B) As (A) but scale expanded to constant ionic strength (1 = 0.15) using the formula I = ~ciz  i and the 
show depression of activity by heparin at low pH. Error bars omitted as assumption, based on titrametric data, that at pH 5.5 histamine was 13% 
S.E.M. values are less than or equal to symbol diameter (n = 3). monovalent and 87% divalent, and at pH 7.6 it was virtually all monova- 
lent. Values relative to the activity with no histamine or other addition are 
expressed as mean_+S.E. (n=3) .  Significant difference by Student's 
Table 1 t-test from activity in the absence of histamine, but in the presence of the 
Effect of pH, heparin and BSA on the kinetic constants of purified indicated addition: * P < 0.05, * * P < 0.01, * * * P < 0.005, * * * * P 
chymase for a peptide substrate (SncAAPF-pNA) < 0.001. 
pH Addition K m Vma x
(mM) (/zmol rain- l mg i ) 
7.5 none 0.80 44 
7.5 100/zg/ml heparin 0.98 62 
7.5 100/xg/ml BSA 1.04 92 
6.0 none 0.85 32 
6.0 100/zg/ml heparin 1.23 32 
6.0 100/xg/ml BSA 1.23 39 
5.5 none 0.90 19 
5.5 100/zg/ml heparin 1.60 17 
5.5 100/xg/ml BSA 1.87 27 
Purified chymase (70 ng ml -I for pH 7.5, 150 ng ml- i  for pH 6.0 and 
5.5) was assayed without any addition or in the presence of heparin or 
BSA.Buffers were 50 mM acetic acid, 50 mM Aces, 100 mM Tris, 50 
mM NaCI, adjusted to the given pH with either HCI or NaOH (I = 0.15). 
Substrate concentrations ranged from 0.25 to 4.0 mM, n = 3 for each 
combination of [S], pH and addition. 
3.5. H is tamine  
At  constant  ionic  s t rength ( I=0.15) ,  h i s tamine  had 
neg l ig ib le  e f fect  on the act iv i ty o f  pur i f ied  chymase  on its 
own or  in the presence  o f  BSA at pH 7.6 (Fig. 4A) ,  and a 
smal l  inh ib i tory  e f fect  at pH 5.5 (Fig. 4B).  The  act ion o f  
h i s tamine  in the presence  o f  hepar in  was  more  complex :  it 
inh ib i ted  the enzyme at pH 7.6 and s t imulated it at pH 5.5, 
but  not  to the extent  that it over rode  the s t imulat ing e f fect  
o f  hepar in  at pH 7.6, or  its inh ib i t ing ef fect  at pH 5.5. 
H is t id ine  (50 mM)  as contro l  had no s ign i f icant  e f fect  on 
act iv i ty in any o f  the t reatments .  
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4. Discussion 
The pH profile of chymase is similar to that which has 
been reported for chymotrypsin with a steadily rising, 
almost sigmoidal increase with increasing pH [35]. Such a 
profile is indicative of activity being dependent on the 
ionization state of a single amino acid residue, presumably 
at the active site. In both the presence and absence of 
heparin, chymase was quite stable at acidic pH, which is 
what would be expected for an enzyme stored under such 
conditions in the mast cell granule. That it proved to be 
more stable at pH 5.5 than at pH 7.5 could be due to 
reduced autodegradation resulting from lowered activity. 
Autodegradation of chymase has been reported [18] and 
could account for the low molecular mass bands seen on 
SDS-PAGE gels (Fig. 1). 
Heparin was found to enhance the pH-dependent regula- 
tion of chymase by increasing activity at pH 7.5 by 33% 
and decreasing it at pH 5.5 by 40%. This was achieved by 
both a decrease in Vma x relative to enzyme alone and an 
increase in K m as pH decreased, while maintaining hyper- 
bolic kinetics. Thus, at pH 5.5 heparin behaved as a mixed 
inhibitor, even though at pH 7.5 it behaved as an activator. 
In contrast o its potent inhibition of tryptase [26], his- 
tamine has little effect of its own on chymase activity, but 
does appear to modulate the action of heparin on chymase, 
reducing both its ability to stimulate nzyme activity at pH 
7.6 and its ability to inhibit it at pH 5.5. These observa- 
tions could be due to a weakening of the interaction 
between heparin and chymase. Such an effect would have 
to be specific to histamine as histidine had no effect and 
all experiments were conducted at constant ionic strength. 
BSA, in contrast to heparin, enhanced activity at all pH 
values. It consistently had a higher Vma x than enzyme 
alone, which is what would be expected if it were increas- 
ing the total amount of chymase in solution by blocking 
adsorption to the microtitre plate (i.e., as  gma x = kcat[ETo T ], 
it acts by increasing [Evo v] rather than kcat). However, as 
a protein, BSA is a potential substrate for chymase and rat 
serum albumin has been reported to be cleaved by rat 
chymase [36]. Therefore, it would be expected to behave 
as a competitive inhibitor when monitoring the hydrolysis 
of a chromogenic substrate and raise the K m for that 
substrate. This was, indeed, observed, but it is not clear 
why the K m values should be nearly the same as those 
derived in the presence of heparin. 
Modest stimulation by heparin for the cleavage of syn- 
thetic peptide substrates has been noted for dog [37], rat 
[38] and human [39] chymase. Evaluation of the effect of 
heparin is rendered ifficult by the tendency of chymase to 
adsorb to surfaces. Adsorption to polystyrene surfaces 
should be primarily hydrophobic in character and any 
blocking agents would be expected to be amphipathic. 
Although proteins and detergents meet this criterion, sul- 
fated polysaccharides do not. Accordingly, chondroitin 
sulfate C and dextran sulfate did not enhance the activity 
of chymase, whereas heparin did. Furthermore, histamine 
had no significant effect on the action of BSA on chymase 
relative to its action on the enzyme alone. Taken together, 
these results suggest that the mechanism of action of 
heparin on chymase is different from that of BSA, and that 
the stimulation with peptide substrates een at pH 7.5 
could be physiologically relevant. 
The modest effect of heparin on chymase activity to- 
wards peptides may be a consequence of their small size. 
With larger substrates, more dramatic results have been 
reported. Heparin was found to inhibit the degradation of 
proteoglycans by dog chymase and also the secretagogue 
activity of this enzyme on cultured bovine airway gland 
serous cells [37]. With rat chymase, also known as rat mast 
cell proteinase 1 (RMCP-I), heparin produced a ninefold 
increase in the enzyme's ability to inactivate thrombin 
[38]. Heparin has been found to affect the action of human 
chymase on interstitial procollagenase in two ways: it 
accelerated the cleavage step which forms active enzyme 
and increased the specificity of chymase so that there was 
no further degradation of the collagenase [40]. 
The results of the present study, together with the 
results of studies of the expression of recombinant chy- 
mase [14], lead us to make the following proposals for the 
control of enzyme activity during the synthesis, storage, 
and release of chymase. During synthesis, the nascent 
polypeptide chain is injected into the lumen of the endo- 
plasmic reticulum with the cleavage of the signal peptide 
to produce the proenzyme. This catalytically inactive 
prochymase is processed through the Golgi apparatus and 
directed to the developing mast cell granule, with the 
N-terminal propeptide possibly serving as a tag for intra- 
cellular trafficking. As the granule matures, acidification 
occurs, activating an N-terminal dipeptidase to remove the 
propeptide. The mature chymase, in tight association with 
heparin, is kept relatively inactive by the acidic pH. The 
heparin also restricts diffusion of the chymase, further 
limiting hydrolysis of any other protein present. It has also 
been demonstrated that isolated mast cell granular matrices 
expand in the presence of monovalent cations and con- 
dense in the presence of divalent cations so that at pH 5.5, 
histamine, being mostly in the divalent form, causes a 
condensation of the heparin matrix [41], thus restricting 
diffusion to an even greater extent. 
Upon mast cell degranulation, the matrix expands 
rapidly, partly due to the neutralisation of histamine by the 
increase in pH, partly due to displacement of histamine by 
sodium ions [41], and possibly abetted by local electric 
potentials [42]. Chymase is rapidly activated by the in- 
crease in pH, and although histochemical evidence sug- 
gests that it remains bound to the matrix [39], the expan- 
sion of the matrix allows for the diffusion of substrates to 
the fully active enzyme. Locally high concentrations of 
histamine would have very little effect on activity. Further 
work is needed to confirm the various steps in this scheme, 
especially the covalent processing of the prochymase in 
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the Golgi apparatus and maturing granule. It will also be 
important to establish the effects of heparin on activity of 
the enzyme towards physiological substrates and on the 
inactivation of chymase by serum and tissue proteinase 
inhibitors. 
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